PD1-1-7: Primary synchronous lung cancer detected using autofluorescence bronchoscopy  by Kim, Ju Ock et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS416
polymorphisms in the survivin gene by direct sequencing of genomic 
DNA samples from 27 healthy Koreans, and then performed a case-
control study to evaluate the association of the polymorphisms with 
lung cancer risk. The survivin genotypes were determined by PCR am-
pliﬁcation and melting curve analysis in 582 lung cancer patients and in 
582 healthy controls. We identiﬁed 8 single nucleotide polymorphisms 
(SNPs): 6 known SNPs [-644T>C, -625G>C, -31C>G, 9194A>G 
(K129E), 9386T>C and 9809T>C] and 2 novel SNPs (9974C>T and 
10347G>A). Among the SNPs studied, the -31C>G genotype distribu-
tion was signiﬁcantly different between the cases and controls (P = 
0.04). Individuals with at least one -31G allele were at a signiﬁcantly 
decreased risk of lung cancer compared to those individuals with the 
-31CC genotype (OR = 0.74, 95% CI = 0.57-0.96, P = 0.02). When the 
lung cancer cases were categorized by tumor histology, the -31G allele 
was associated with a signiﬁcantly decreased risk of adenocarcinoma 
(OR = 0.59, 95% CI = 0.41-0.84, P = 0.003). Consistent with the results 
of the genotyping analysis, the -625G/-31G/9194A/9809T haplotype 
carrying the -31G allele was associated with a signiﬁcantly decreased 
risk of adenocarcinoma (OR = 0.56, 95% CI = 0.40-0.77, P = 0.0004). 
The promoter assay revealed the -31G allele to have a signiﬁcantly 
lower promoter activity than the -31C allele. These results suggest that 
the survivin -31C>G polymorphism inﬂuences survivin expression, 
thus contributing to the genetic susceptibility to lung cancer.
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Background: Patients with lung cancer have a relative high risk of 
developing secondary primary lung cancers. This study examined the 
additional value of autoﬂuorescence bronchoscopy (AFB) for diagnos-
ing synchronous lung cancers and premalignant lesions.
Methods: Patients diagnosed with lung cancer from January 2005 to 
December 2005 were enrolled in this study. The patients underwent 
a lung cancer evaluation, which included white light bronchoscopy 
(WLB), followed by AFB. In addition to the primary lesions, any abnor-
mal or suspicious lesions detected during WLB and AFB were biopsied.
Results: Seventy-six patients had non-small cell lung cancer (NSCLC) 
and 23 had small cell lung cancer (SCLC). In addition to the primary 
lesions, 84 endobronchial biopsies were performed in 46 patients. Five 
deﬁnite synchronous cancerous lesions were detected in three patients 
with initial unresectable NSCLC and in one with SCLC. The second-
ary malignant lesions found in two patients were considered metastatic 
because of the presence of mediastinal nodes or systemic involve-
ment. One patient with an unresectable NSCLC, two with a resectable 
NSCLC, and one with SCLC had severe dysplasia. The detection 
rate for cancerous lesions by the clinician was 6.0% (6/99) including 
AFB compared with 3.0% (3/99) with WLB alone. The prevalence 
of deﬁnite synchronized cancer was 4.0% (4/99) after using AFB 
compared with 2.0% (2/99) before, and the staging-up effect was 1.0% 
(1/99) after AFB. Since the majority of patients were diagnosed with 
advanced disease, the subjects with newly detected cancerous lesions 
did not have their treatment plans altered, except for one patient with a 
stage-up IV NSCLC who did not undergo radiotherapy. 
Conclusions: Additional AFB is effective in detecting early secondary 
cancerous lesions and is a more precise tool in the staging workup of 
patients with primary lung cancer than with WLB alone.
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The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, 
geﬁtinib (Iressa), was applied for the treatment of non-small lung can-
cer (NSCLC). Recently, EGFR mutations have known to be correlated 
with clinical response in geﬁtinib treatment. However, detection of 
EGFR mutations in tumor tissue has variable limitations, such as that 
biopsy procedure is invasive, the amount of clinical sample is limited, 
and many normal cells could be contaminated during tumor tissue dis-
section which could generate false negative results. It was well known 
that serum free DNA of cancer patients represents genetic changes 
of primary tumors. To evaluate the clinical implication of simple and 
sensitive detection method of EGFR mutation using serum free DNA, 
we examined the EGFR exon 19 and 21 mutation status in serum DNA 
from geﬁtinib treated NSCLC patients using direct sequencing and mu-
tant enriched PCR analysis. Direct sequencing method detected EGFR 
mutation only in 1 patient from total 30 patients (3.3 %). This result 
revealed that direct sequencing method is not suitable for detection 
of low copy number of EGFR mutation from serum DNA. However, 
mutant enriched PCR analysis detected EGFR mutations in 25 patients 
(50%) from total 50 patients. Mutant enriched PCR method detected 
exon 19 mutations in 12 patients (24%), exon 21 mutations in 13 
patients (26%), and both mutations in 1 patients (2%). Out of 8 patients 
who had partial responses (PR) with geﬁtinib treatment, EGFR muta-
tions were noted in 6 patients (75%). Five out of 11 patients (45%) with 
stable disease (SD) showed EGFR mutations. Out of 27 patients with 
progressive disease (PD), EGFR mutations were detected in 13 patients 
(48%). To conﬁrm the results of the mutant enriched PCR analysis, the 
second PCR products were directly sequenced for both exons. In result, 
mutant enriched PCR analysis coincided with direct sequencing analy-
sis in exon 21. In summary, we applied 2 different EGFR mutation de-
tection methods using serum free DNA from geﬁtinib treated patients. 
Mutant enriched PCR analysis is more speciﬁcity and sensitivity than 
direct sequencing. Our data showed correlation with EGFR mutation 
status using mutant enriched PCR method using serum free DNA and 
clinical geﬁtinib responses. The EGFR mutation status in serum free 
DNA might be a convenient and useful biomarker for the prediction of 
clinical response in geﬁtinib-treated NSCLC patient. 
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